Expert Opinion on Biological Therapy

Papers
(The TQCC of Expert Opinion on Biological Therapy is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli76
Biosimilars and access to biologic therapy in immune-mediated diseases59
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol58
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males54
The endosomal-lysosomal system in ADC design and cancer therapy53
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases43
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions41
Aflibercept biosimilars – so near, yet so far32
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?32
IL-4/IL-13 targeted biologics in atopic dermatitis: is their use safe in oncologic patients?31
Antibody drug conjugates for glioblastoma: current progress towards clinical use31
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences28
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era28
Bispecific antibody combination regimens for B-cell non-Hodgkin’s lymphomas28
Signaling new therapeutic opportunities: cytokines in prostate cancer27
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)26
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway26
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden26
Correction25
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma25
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?24
Long-acting delivery and therapies for neovascular age-related macular degeneration23
Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials23
Dual clinical remission in severe asthma and chronic rhinosinusitis with nasal polyps: a comparative review of biologic therapies22
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies22
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?21
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study21
Unmet needs in cervical cancer – can biological therapies plug the gap?21
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)21
An evaluation of guselkumab for the treatment of ulcerative colitis21
Challenges and considerations in developing trispecific CAR-Ts for B-cell malignancies20
Correction20
Predicting and overcoming poor patient responses to sublingual immunotherapy for allergic diseases20
Non-canonical function of erythropoietin and downstream effects of erythropoietin-mediated signaling beyond its role in erythropoiesis20
Cell population data as predictive biomarkers for biologic therapy response in psoriasis20
Correction20
Strategies for extending the half-life of biotherapeutics: successes and complications19
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment19
New biological agents in systemic lupus erythematosus19
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective18
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology18
Dynamics of biological markets with multiple biosimilar competitors in the United States18
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses18
Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives17
Management of proctitis in ulcerative colitis and the place of biological therapies16
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities16
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?16
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer16
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors16
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies16
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease16
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma16
The nail in psoriatic arthritis: new insights into prognosis and treatment16
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy16
Emerging strategies for the prevention and management of chronic graft-versus-host disease15
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward15
Recent advances in delivering RNA-based therapeutics to mitochondria14
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-1914
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials14
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region14
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis14
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations13
Personalizing immunotherapy for renal cell carcinoma: how far have we come?13
Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?13
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection13
Emerging peptide-based technology for biofilm control13
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children13
Tarlatamab for small-cell lung cancer12
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations12
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)12
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives12
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project12
Belimumab patient profile in Spain: evolution during the last decade and future directions12
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma12
An evaluation of pozelimab for the treatment of CHAPLE disease12
Evaluation of biological treatment in pediatric patients with familial Mediterranean fever: a retrospective study of 832 patients12
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan12
Treating psoriasis in the elderly: biologics and small molecules12
Talquetamab for the treatment of relapsed/refractory multiple myeloma: a review of efficacy, safety, and real-world evidence12
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents11
Long-term effectiveness and safety of ustekinumab in patients with Crohn’s disease: real-world evidence11
Correction11
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective11
A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety, and immunogenicity of BAT1806 SC with tocilizumab in healthy Chinese male subjects11
Tremelimumab for the treatment of hepatocellular carcinoma11
Recent developments and future clinical prospects of polyclonal antibody therapies11
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era11
Biosimilars in osteoporosis treatment: focus on denosumab11
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis11
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks11
Efficacy, safety, and ARIA risk of anti–β-amyloid antibodies in early Alzheimer’s disease: a systematic review, meta-analysis, and meta-regression11
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study11
Clinical management and innovation in fracture non-union10
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis10
Epcoritamab in B-cell malignancies: current status and prospects10
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside10
Non-traditional approaches for control of antibiotic resistance10
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study10
Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics10
The role of monoclonal antibodies in the treatment of lupus nephritis10
Prospects of cell chemotactic factors in bone and cartilage tissue engineering10
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma10
Current status and future potential of CD123-based targeted therapies for acute leukemia9
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target9
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer9
Correction9
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials9
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio9
Perspectives on the use of biological therapies for the treatment of asthma in low-middle income countries9
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms9
Antibody therapeutics for epithelial ovarian cancer9
X-linked myotubular myopathy: an untreated treatable disease9
Biologics in rectal cancer9
Sargramostim in acute radiation syndrome9
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis8
Ravulizumab for the treatment of myasthenia gravis8
Biologic therapy through caregivers’ eyes: insights from a multicenter pediatric rheumatology survey8
The future of interleukin gene therapy in head and neck cancers8
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study8
Expression of Concern:8
“Full-naïve” patients: the impact of previous methotrexate, cyclosporine, and acitretin on first-line biologics response in the treatment of moderate-to-severe psoriasis – a monocentric retrospective 8
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa8
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?8
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups8
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells8
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto8
Ex vivo gene therapy for lysosomal storage disorders: future perspectives8
0.30786991119385